Lexicon Pharma (LXRX) Misses Q2 EPS by 4c, Revenues Beat

Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.65), $0.04 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $9.2 million versus the consensus estimate of $8.83 million.

“We achieved 21% growth in XERMELO net sales in the U.S. for the second quarter of 2020 compared to the prior-year period, underscoring the importance of our product to patients,” said Lonnel Coats, Lexicon’s president and chief executive officer. “In these unprecedented times of the COVID-19 pandemic, I am proud of the commitment and dedication of our employees to our mission to pioneer medicines to transform patients’ lives. We continue to make progress on our pipeline with initiation of screening of patients in the Phase 2 RELIEF-DPN-1 study for LX9211 in patients with diabetic peripheral neuropathic pain. We look forward to providing additional updates later this year.”

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.

You May Also Be Interested In

• Occidental Petroleum releases Q2 2026 earnings considerations
• HSBC Upgrades Capital One Financial (COF) to Buy
• Peapack Private names Paul Kotronis as senior CRE director